Nutex Health Surges 10% on Share Buyback Extension and Strong Financials

Summary
• Nutex Health (NUTX) surges 10.06% to $145.00, hitting an intraday high of $150.43
• Company extends $25M share repurchase program through March 2026
• Q3 2025 revenue jumps 240% to $267.8M, net income turns positive at $55.4M
• Sector peers react to DOJ’s $14.6B healthcare fraud takedown

Nutex Health’s stock erupted in late trading as the company announced a six-month extension of its $25M share repurchase program, signaling confidence in its long-term strategy. The move coincided with a 240% revenue surge in Q3 2025 and a dramatic turnaround from a $8.8M loss to $55.4M net income. With the stock trading near its 52-week high of $184.28, investors are weighing the impact of aggressive buybacks against sector-wide regulatory scrutiny.

Share Repurchase Extension Fuels Investor Optimism
Nutex Health’s 10.06% intraday rally was directly triggered by the board’s decision to extend its $25M stock repurchase program through March 31, 2026. The program, now operational under Rule 10b-18 and 10b5-1 frameworks, aims to offset dilution from stock compensation tied to new hospital developments. This move underscores management’s confidence in the company’s financial health, evidenced by Q3 2025 results: revenue surged to $267.8M (up 240% YoY), net income turned positive at $55.4M (vs. $8.8M loss in Q3 2024), and free cash flow reached $174M. The buyback extension also aligns with a strong balance sheet, including a 3.2 current ratio and $932M market cap, suggesting capacity to execute the program without compromising operational flexibility.

Healthcare Sector Volatility Amid Fraud Crackdown
The broader healthcare sector faced mixed signals as the DOJ announced a record $14.6B fraud takedown targeting 324 defendants, including 96 medical professionals. While this regulatory action could indirectly benefit Nutex Health by reinforcing trust in legitimate healthcare providers, the sector’s risk profile remains elevated. Tenet Healthcare (THC), a sector leader, saw a modest 0.21% intraday gain, contrasting with NUTX’s explosive move. The disparity highlights Nutex’s unique catalyst—its buyback-driven value proposition—versus sector-wide macro concerns.

Technical Bull Case and Strategic Buy-Write Opportunities
• 200-day MA: $105.11 (well below current price)
• RSI: 54.4 (neutral, suggesting momentum retention)
• MACD: 3.17 (bullish divergence from signal line at 2.63)
• Bollinger Bands: Price at 145.0 (above upper band at 143.48, indicating overbought conditions)

Nutex Health’s technicals paint a compelling short-term bullish case. The stock has pierced its 52-week high of $184.28 and is trading 36% above its 200-day MA, suggesting strong near-term momentum. Key support levels at $131.12 (30D) and $117.34 (200D) could act as psychological floors if the rally consolidates. Given the absence of listed options, a buy-write strategy using the 200-day MA as a trailing stop could capitalize on the upward trend. Investors should monitor the 100-day MA ($103.78) as a critical threshold for trend continuation.

Backtest Nutex Health Stock Performance
I attempted to retrieve historical price data for Nutex Health (ticker: NUTX) so I could identify every session since 2022 in which the stock experienced a ≥ 10 % intraday surge, but I received an error from the data-feed (“asset base info not found”). That normally happens when the data provider doesn’t have that symbol in its coverage universe (or it’s listed under a different code such as an exchange-qualified ticker like “NUTX.OQ”, “NUTX US”, etc.).Could you please confirm one of the following so I can proceed?1. The exact ticker / exchange code you’d like me to use (e.g. “NUTX.OQ” for NASDAQ). 2. If you have your own file (CSV, Excel, etc.) with daily OHLC data for NUTX that I can work with. Once we have a usable price stream I can:• detect every ≥ 10 % intraday surge day, • run the event-driven back-test (entry at next day’s open, or any other rule you prefer), and • deliver the statistics and visualization of the strategy’s historical performance.

Nutex Health’s Bull Run: A Buy-Write Play on Shareholder Value
Nutex Health’s 10% surge reflects a perfect storm of strategic buybacks, robust financials, and sector-specific tailwinds. With $174M in free cash flow and a 3.2 current ratio, the company is well-positioned to execute its $25M repurchase program without operational strain. Technicals reinforce the bullish narrative, with RSI and MACD indicators suggesting sustained momentum. Sector peers like Tenet Healthcare (THC) gained 0.21%, but NUTX’s unique catalyst—its aggressive buyback—makes it a standout. Investors should watch the $131.12 support level and consider a buy-write strategy to lock in gains while maintaining exposure to the upward trend.